Literature DB >> 29361476

Severe idiopathic pulmonary fibrosis: A clinical approach.

R Lipsi1, D Mazzola1, A Caminati1, D Elia1, C Lonati2, S Harari3.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a devastating progressive disease associated with a high mortality rate. Novel antifibrotic therapies have been recently demonstrated to slow disease progression and improve survival. However, the management of IPF remains a difficult challenge, since lung complications can still occur, particularly in patients with advanced-stage disease. This paper highlights the most common complications and difficult tasks related to severe IPF such as acute exacerbation of the disease, development of lung cancer, rapid disease progression, and indication for lung transplantation.
Copyright © 2018 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute exacerbation of IPF; Lung cancer; Lung transplantation; Nintedanib; Palliation; Pirfenidone

Mesh:

Year:  2018        PMID: 29361476     DOI: 10.1016/j.ejim.2018.01.014

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  2 in total

1.  RNA sequencing of transplant-stage idiopathic pulmonary fibrosis lung reveals unique pathway regulation.

Authors:  Pitchumani Sivakumar; John Ryan Thompson; Ron Ammar; Mary Porteous; Carly McCoubrey; Edward Cantu; Kandasamy Ravi; Yan Zhang; Yi Luo; Denis Streltsov; Michael F Beers; Gabor Jarai; Jason D Christie
Journal:  ERJ Open Res       Date:  2019-08-12

2.  Survival benefit of lung transplantation compared with medical management and pulmonary rehabilitation for patients with end-stage COPD.

Authors:  Irina Timofte; Marniker Wijesinha; Roumen Vesselinov; June Kim; Robert Reed; Pablo G Sanchez; Nicholas Ladikos; Si Pham; Zachary Kon; Keshava Rajagopal; Steven M Scharf; Robert Wise; Alice L Sternberg; David Kaczorowski; Bartley Griffith; Michael Terrin; Aldo Iacono
Journal:  ERJ Open Res       Date:  2020-04-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.